Lot-document scope confirmed before quotation · Research use only
  • Specification Review
  • Lot Documents on Request
  • Business Support · Xi’an
  • Destination Eligibility Confirmed
西安诺和达生物科技有限公司

Research & insights

Peptide HPLC: why 214 nm and 280 nm are not interchangeable

By NHD Technical TeamPublished
Comic illustration for Peptide HPLC: why 214 nm and 280 nm are not interchangeable
AI-generated conceptual comic illustration; not a photograph of an NHD facility or supplied lot.

An HPLC instrument separates sample components. A UV detector then measures how much light they absorb at a selected wavelength. That wavelength is part of the method, not a decorative number on the report. Changing it can change which components are easy to see.

What do 214 nm and 280 nm mean?

The numbers are light wavelengths, measured in nanometres. Thermo Fisher’s peptide-analysis discussion describes detection around 214 nm using peptide UV absorbance. It is one common approach, not a universal requirement for every peptide or every impurity. [1]

Thymosin alpha-1 shows why the choice matters

In its application note on synthetic thymosin alpha-1, Thermo Fisher used UV detection at 214 nm and explained that this peptide has no aromatic amino acids and no UV absorption at 280 nm in that discussion. The example shows why a familiar protein-detection wavelength may be unsuitable for a particular peptide. It is that provider’s method example, not an NHD batch result. [2]

A percentage still depends on what was measured

For a hypothetical calculation, a main-peak area of 980 units out of 1,000 included area units gives 98%. That is an area ratio at the chosen detector settings. It cannot describe a component that the method does not detect or separate. A different response from an impurity can also affect how its area relates to its mass.

Compare methods before comparing headline numbers

Two reports labeled “HPLC purity” may use different wavelengths, columns, gradients or integration rules. A difference in percentage is therefore a reason to inspect the methods, not immediate proof that one supplier has better material. Ask which peaks were included and whether relevant impurities can be resolved.

Ask for the method details with the product

For a thymosin alpha-1 enquiry, specify the molecular form and quantity, then ask which purity method and supporting chromatogram could be provided for the proposed material. Check the NHD product family and HPLC guide together. The product page alone does not confirm a particular batch has been tested.

Useful links

For laboratory research, development and manufacturing only. Not for human or veterinary use.

Sources and examples

Reference records explain the topic; they do not establish NHD stock, a supplied lot’s results or clinical suitability. Examples explicitly labeled as hypothetical are calculations, not test data.

Sources & editorial method

AI-assisted drafting, source checks, translation and generated comic illustration. This is not independent peer review or supplied-lot verification.

2 linked records are listed in the references below. Read the editorial and AI-assistance policy.

How to interpret this article

Reference data and teaching examples are separated from NHD lot results; product specifications and availability require confirmation.

Research-use boundary: Catalog materials discussed on this website are for laboratory research, development and manufacturing use only, not for human or veterinary use. This content is not medical advice and does not provide administration instructions.

Primary records and authoritative sources

  1. Thermo Fisher: mass spectrometry and peptide UV detectionThermo Fisher: mass spectrometry and peptide UV detection. Accessed 2026-10-03.
  2. Thermo Fisher: purity analysis of synthetic thymosin alpha-1, Protein Therapeutics Applications Notebook, printed page 60Thermo Fisher: purity analysis of synthetic thymosin alpha-1, Protein Therapeutics Applications Notebook, printed page 60. Accessed 2026-10-03.

Editorial source check: Codex AI editorial · 2026-10-03